Appeals Court Upholds Prelimary Injunction Prohibiting Sales of Biotechnology General's Growth Hormone Product.SOUTH SAN FRANCISCO South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , Calif.--(BUSINESS WIRE)--April 8, 1996-- Genentech, Inc. (NYSE NYSE See: New York Stock Exchange : GNE GNE Gateway Network Element (data communications) GNE Game Neverending (MMORPG) GNE Gross National Expenditure GNE Game Networking Engine GNE Graphical Network Editor (Nortel) ) today announced that a preliminary injunction A temporary order made by a court at the request of one party that prevents the other party from pursuing a particular course of conduct until the conclusion of a trial on the merits. A preliminary injunction is regarded as extraordinary relief. preventing Biotechnology General Corporation and its affiliates (BTG BTG BIT (Built-In Test) Target Generator BTG Bridging the Gap BTG British Technology Group BtG Betreuungsgesetz (Germany) BTG Biomass Technology Group BV BTG Begbies Traynor Group ) from marketing their human growth hormone human growth hormone (HGH): see growth hormone. product in the United States has been upheld by the Court of Appeals for the Federal Circuit. The preliminary injunction states that it will be in effect pending final determination of the action. Genentech claims that BTG infringes Genentech's U.S. patents that relate to the manufacture of human growth hormone. On June 28, 1995 a District Court in New York granted a preliminary injunction preventing BTG from marketing their human growth hormone product in the United States. Subsequent to that decision, BTG appealed the decision to the Court of Appeals for the Federal Circuit. Today, that appellate court upheld the preliminary injunction against BTG. "We are very pleased that the Court of Appeals for the Federal Circuit has upheld the preliminary injunction against BTG," said Stephen Raines, Genentech's vice president for Intellectual Property. "Genentech remains convinced that the sale of BTG's product will be permanently prohibited at the end of the full hearing before the District Court, which will be held at a later date." Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures, and markets human pharmaceuticals for significant unmet medical needs. The Company has headquarters in South San Francisco and is traded on the New York and Pacific stock exchanges under the symbol GNE. CONTACT: Genentech, Inc. Kathleen Rinehart, 415/225-8681 (Media Contact) Lisa Brock, 415/225-1034 (Investor Contact) |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion